A 2013 study in the International Journal of Cardiology found that the bergamot polyphenolic extract, when taken with the popular cholesterol-lowering rosuvastatin, enhanced the potency of the statin
NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone
The data will be presented during the European Society of Cardiology congress1 taking place between 30 August and 3 September 2014 in Barcelona. ATLANTIC was designed to evaluate
The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers
Bile acids are essential for regulating cholesterol metabolism and the intestinal digestion and absorption of fat. Their signaling functions play an important role in chronic disorders, sepsis, or
Boehringer Ingelheim continues to grow the evidence base for Pradaxa to improve care for patients at risk of blood clots and today announces the initiation of Phase III
This study was a 10-year epidemiology study, conducted by the University of Pennsylvania and Division of Research at Kaiser Permanente Northern California (KPNC), and was designed to investigate
The tender offer is being made pursuant to the previously announced merger agreement dated 22 August 2014 among Roche Holdings, Inc., Klee Acquisition Corporation, a wholly owned subsidiary
Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). Results from the four ongoing trials, all of which met their primary efficacy endpoint, will
QIDP status is granted to drugs which act against pathogens which have a high degree of unmet need in their treatment and are identified by Centre for Disease
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.